Navigation Links
Colorectal cancer
Date:7/1/2009

etastases than in non-metastatic tumors.

"Our investigations show that the particular gene BAMBI is associated with two import signaling pathways and thus promotes metastasis formation," Dr. Fritzmann said. "These signaling pathways (Wnt and TGF-beta) are, among other things, important in the developing embryo."

In the future the researchers want to investigate the role of the other 114 genes more closely, in order to better understand the individual steps of metastasis formation.

Aim To predict at an early stage whether the tumor will spread

Dr. Fritzmann hopes the research findings will help determine early on whether a tumor has metastatic potential. The doctors could then adapt the therapy accordingly.


'/>"/>

Contact: Barbara Bachtler
bachtler@mdc-berlin.de
49-309-406-3896
Helmholtz Association of German Research Centres
Source:Eurekalert  

0

GOOD

Page: 1 2

Related biology news :

1. Study finds colorectal cancer rates increasing worldwide
2. Rural areas able to increase screening capacity for colorectal cancer
3. Hormone therapy associated with reduced colorectal cancer risk
4. Scientists discover major genetic cause of colorectal cancer
5. Colorectal cancer screening rates still too low
6. Curry-derived molecules might be too spicy for colorectal cancers
7. Interleukin-8, key marker for colorectal cancer treatment
8. A search for biomarkers for early detection of colorectal cancer
9. New e-science service could accelerate cancer research
10. Genetically engineered mice yield clues to knocking out cancer
11. New biomarker method could increase the number of diagnostic tests for cancer

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Colorectal cancer
Colorectal cancer
(Date:11/4/2009)...AD, Calif., Oct. 23 GenVault Corpo...e management for genomic discovery, medicine and i...Ph.D., GenVault,s President and CEO, will be prese...ce on October 26th and 27th in La Jolla, CA. ,,...an overview of the company together with recent cu...
(Date:11/4/2009)...PEL HILL Scientists at the University of North Ca...niversity of California, San Francisco have develo...ct new target diseases for existing drugs. , The... compares how similar the structures of all known ...ers -- known as ligands -- of disease targets with...
(Date:11/3/2009)...WI, NOVEMBER 4, 2009 -- The world,s greatest wine...e variety, human input, and something called the "...ite, soil, and climate. , Experts will discuss...posium on Wednesday, Nov. 4 in Pittsburgh. "Terro...ted in two parts at the 2009 Annual Meetings of th...
Breaking Biology News(10 mins):GenVault Corporation to Present at the 2009 BIOCOM Investor Conference 2Study points to new uses, unexpected side effects of already existing drugs 2Great wines come from great soils 2Texas Health Hospitals to Receive Financial Awards for Quality 54624 1Texas Health Hospitals to Receive Financial Awards for Quality 54624 2Texas Health Hospitals to Receive Financial Awards for Quality 54624 3Dr Siegals Cookie Diet Book Available at Amazon Barnes 26 Noble and Indigo Books 54622 1Dr Siegals Cookie Diet Book Available at Amazon Barnes 26 Noble and Indigo Books 54622 2Dr Siegals Cookie Diet Book Available at Amazon Barnes 26 Noble and Indigo Books 54622 3Dr Siegals Cookie Diet Book Available at Amazon Barnes 26 Noble and Indigo Books 54622 4Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors 13592 1Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors 13592 2
... November 20, 2007 SAGE and the Hindawi Publishi...t to jointly launch and publish a suite of fully O...gic partnership that places SAGE as the largest ac...pen Access journals, marking the companys continue...arly research. SAGE is the worlds fifth largest jo...
... Using supercomputers to compare portions of the ...ers at Cornell have discovered some 300 previously... several hundred genes already known., The discove...sections of genetic code that do something useful ...search is reported by Adam Siepel, Cornell assista...
... November 19, 2007 For the first time, a study b...l of Public Health, is linking asthma with post-tr...tudy of male twins who were veterans of the Vietna... and PTSD is not primarily explained by common gen...twin pairs, who had lived together in childhood, a...
Other Biology News:SAGE and Hindawi announce landmark open access agreement 2Evolutionary comparison finds new human genes 2Evolutionary comparison finds new human genes 3Asthma link to post-traumatic stress disorder, says Mailman School of Public Health study 2
(Date:11/6/2009)... The agenda for Arrowhead’s 2010 Personalize...o take place on February 22-24, 2010 in Philadelph...ce we will highlight key issues in forming partner...experiences. , Minneapoli...rrowhead’s 2010 Personalized Medicine Partn...
(Date:11/5/2009)...Nov. 5 GenVec, Inc. (Nas... for the third quarter ended September 30, 2009. G...er share) for the three months ended September 30,...8 per share) in the comparable quarter of 2008. Fo...,s net loss was $14.1 million ($0.15 per share), c...
(Date:11/5/2009)...ov. 5 DSM Pharmaceutical Products ...lliance with Galenix, Saint Jean D,Illac, France, ...anufacturing partner for Galenix commercial produc...ollaborate on business development opportunities c...sed on the strength of Galenix in drug product dev...
(Date:11/5/2009)...if., Nov. 5 ThermoGenesi...novative products for processing and storing adult...quarter of fiscal 2010. ,, For the quarter ende...s of $5.2 million, a 15 percent increase over reve...go. The Company said the key contributors to the g...
Breaking Biology Technology:Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8
...tics, Inc. (OTC Bulletin Board: NWBO; AIM: NWBS an...settlement of a putative securities class action l...ecurities Litigation , No. C-07-1254-RAJ. The Com... which is to be funded out of insurance proceeds. ...ditional details about the settlement can be found...
...ics, Inc.,(Nasdaq: OREX ) today announced that t...igational product Contrave(R) (naltrexone sustaine...d key secondary endpoints, showing a,significant r...f,cardiovascular risk and reductions in selected f...ncluded an intensive diet and exercise behavior,mo...
...rporation (Nasdaq: MATK ) announced today that i...CR XChange investor conference. The conference is...onarch Beach Resort & Spa in Dana Point, Calif...d David Abramson, President, will be presenting on...live audio webcast of Martek,s presentation can be...
Other Biology Technology:Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action 2Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action 3Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints 2Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints 3Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints 4Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints 5Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints 6Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints 7
Rabbit Anti-Ca2+ Channel Ca gamma 2 Polyclonal Antibody, Unconjugated from BD Biosciences Pharmingen
Rabbit Anti-Nuclear Receptor Coactivator 2 (NCOA2) Polyclonal Antibody, Agarose Conjugated from Novus Biologicals
Anti-Monocarboxylate Transporter 2 (MCT2) Polyclonal Antibody, Unconjugated from CHEMICON
Mouse Anti-Human Kallikrein 2 Monoclonal Antibody, Unconjugated, Clone 6B7 from ImmuQuest Ltd.
Biology Products: